Biography:
Prof. Fuad Fares has completed his M.Sc. and D.Sc studies at the Faculty of Medicine, Technion-Israel Institute of Technology, and postdoctoral studies at the Department of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri. He is a full professor at University of Haifa. During his studies, he developed a long-acting human follitropin (FSH). This hormone was approved by the European Commission as “ELONVA” for clinical use. He is the founder and the initiator of PROLOR Biotech Start-Up Company for "designing long-acting recombinant proteins". He is the founder of CanCuRx start-up company for treatment of cancer. He has published more than 110 manuscripts in reputed journals and 17 patents.